SOAANZ is an FDA approved loop diuretic for the treatment of edema associated with heart failure or renal disease
SOAANZ is a novel torsemide formulation that releases drug slowly and may help Patients who are having Issues with continued edema
SOAANZ has no generic therapeutic equivalents!
SOAANZ may help heart failure and chronic kidney disease patients who are experiencing issues of volume overload
Get SOAANZ® at a discount from GoodRx
Click here for a discount coupon
Key Benefits Of SOAANZ:
SOAANZ releases torsemide slowly but retains diuretic effectiveness over a day.
Have a look at some key benefits of SOAANZ:
Releases Drug Slowly
Induces gradual diuresis
Duration of action 6-8 hours.
Highlights Of Prescribing Information
These highlights do not include all the information needed to use SOAANZ® safely and effectively. See full prescribing information for SOAANZ.
SOAANZ (torsemide) tablets, for oral use
Contraindications
Indications And Usage
SOAANZ is a loop diuretic indicated in adults for the treatment of edema associated with heart failure or renal disease. (1)
Dosage And Administration
The recommended initial dose is 20 mg orally once daily. Titrate dose by approximately doubling until desired diuretic response is obtained. Doses above 200 mg have not been studied.(2)
Tablets: 20 mg, 40 mg and 60 mg (3)
Hypersensitivity to SOAANZ, anuria, and hepatic coma. (4)
-
Hypotension and worsening renal function: monitor volume status and renal function periodically (5.1)
-
Electrolyte and metabolic abnormalities: monitor serum electrolytes and blood glucose periodically. (5.2)
-
Ototoxicity (5.3, 7.6)
Adverse Reactions
Discontinuation of therapy due to adverse reactions occurred in 6% of patients treated with SOAANZ (6.1).
To report SUSPECTED ADVERSE REACTIONS, contact Sarfez Pharmaceuticals Inc. at 1-877-8-SARFEZ or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Drug Interactions
-
Non-steroidal anti-inflammatory drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects; risk of renal impairment. (7.1)
-
CYP2C9: Concomitant use with CYP2C9 inhibitors can decrease torsemide clearance. Torsemide may affect the efficacy and safety of sensitive CYP2C9 substrates or of substrates with a narrow therapeutic range, such as warfarin or phenytoin. (7.2)
-
Cholestyramine: Decreased exposure of SOAANZ. (7.3)
-
Organic anion drugs: may decrease diuretic activity of SOAANZ. (7.4)
-
Lithium: Risk of lithium toxicity. (7.5)
-
Renin-angiotensin inhibitors: Increased risk of hypotension and renal impairment. (7.7)
-
Radiocontrast agents: Increased risk of renal toxicity. (7.8)
-
Corticosteroids and ACTH: Increased risk of hypokalemia. (7.9)